keyword
MENU ▼
Read by QxMD icon Read
search

zika vaccine

keyword
https://www.readbyqxmd.com/read/28820694/differential-neurovirulence-of-african-and-asian-genotype-zika-virus-isolates-in-outbred-immunocompetent-mice
#1
Nisha K Duggal, Jana M Ritter, Erin M McDonald, Hannah Romo, Farshad Guirakhoo, Brent S Davis, Gwong-Jen J Chang, Aaron C Brault
Although first isolated almost 70 years ago, Zika virus (ZIKV; Flavivirus, Flaviviridae) has only recently been associated with significant outbreaks of disease in humans. Several severe ZIKV disease manifestations have also been recently documented, including fetal malformations, such as microcephaly, and Guillain-Barré syndrome in adults. Although principally transmitted by mosquitoes, sexual transmission of ZIKV has been documented. Recent publications of several interferon receptor knockout mouse models have demonstrated ZIKV-induced disease...
August 14, 2017: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/28818572/ribavirin-inhibits-zika-virus-zikv-replication-in-vitro-and-suppresses-viremia-in-zikv-infected-stat1-deficient-mice
#2
Naganori Kamiyama, Ryusuke Soma, Shinya Hidano, Kei Watanabe, Hiroshi Umekita, Chiaki Fukuda, Kaori Noguchi, Yoshiko Gendo, Takashi Ozaki, Akira Sonoda, Nozomi Sachi, Lucky Ronald Runtuwene, Yumako Miura, Etsuro Matsubara, Shigeru Tajima, Tomohiko Takasaki, Yuki Eshita, Takashi Kobayashi
Zika fever, a mosquito-borne infectious disease caused by Zika virus (ZIKV), is an epidemic disease for which no effective therapy has been established. The recent outbreaks of ZIKV in Brazil and French Polynesia have been linked to a considerable increase in the incidence of fetal microcephaly and other diseases such as Guillain-Barre syndrome. Because there is currently no specific therapy or vaccine, the early exploitation of a method to prevent expansion of ZIKV is a high priority. To validate commonly used antiviral drugs, we evaluated the effect of ribavirin, a drug used to treat hepatitis C with interferon-β (IFN-β), on ZIKV replication...
August 14, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28814523/screening-of-fda-approved-drugs-for-inhibitors-against-japanese-encephalitis-virus-infection
#3
Shaobo Wang, Yang Liu, Jiao Guo, Peilin Wang, Leike Zhang, Gengfu Xiao, Wei Wang
Japanese encephalitis virus (JEV), an arthropod-borne flavivirus, is a major cause of acute viral encephalitis in humans. There is no approved drug available for JEV-specific treatment, and the vaccines are not effective against all clinical JEV isolates. Herein, a high-throughput screening was performed against JEV from an FDA-approved drug library. Five hit drugs were identified that inhibited JEV infection with a selective index > 10. Antiviral activities of these five hit drugs against other flavivirus, including Zika virus, were also validated...
August 16, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28814522/characterization-of-cis-acting-rna-elements-of-zika-virus-by-using-a-self-splicing-ribozyme-dependent-infectious-clone
#4
Zhong-Yu Liu, Jiu-Yang Yu, Xing-Yao Huang, Hang Fan, Xiao-Feng Li, Yong-Qiang Deng, Xue Ji, Meng-Li Cheng, Qing Ye, Hui Zhao, Jian-Feng Han, Xiao-Ping An, Tao Jiang, Bo Zhang, Yi-Gang Tong, Cheng-Feng Qin
Zika virus (ZIKV) has caused significant outbreaks and epidemics in the Americas recently, raising global concern due to its ability to cause microcephaly and other neurological complications. A stable and efficient infectious clone of ZIKV is urgently needed. However, the instability and toxicity of flavivirus cDNA clones in E. coli hosts has hindered the development of ZIKV infectious clones. Herein, using a novel self-splicing ribozyme-based strategy, we have generated a stable infectious cDNA clone of a contemporary ZIKV strain imported from Venezuela to China in 2016...
August 16, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28811170/zika-virus-research-models
#5
REVIEW
Jessica L Kublin, James B Whitney
The 2015 Brazilian Zika virus outbreak sparked a rapid response to control the spread of the virus. What was first understood to be a mild self-resolving infection is now linked to significant neurological defects in both neonates, and adults. The WHO declared the 2016 Zika epidemic a public health emergency and issued an unprecedented recommendation to women in affected regions to delay pregnancy until the risks surrounding Zika virus could be understood, or the epidemic contained. Since that time, considerable effort has been dedicated to understanding Zika transmission and pathogenesis to aid the development of drugs and vaccines...
August 12, 2017: Virus Research
https://www.readbyqxmd.com/read/28806786/an-economic-evaluation-of-vector-control-in-the-age-of-a-dengue-vaccine
#6
Christopher Fitzpatrick, Alexander Haines, Mathieu Bangert, Andrew Farlow, Janet Hemingway, Raman Velayudhan
INTRODUCTION: Dengue is a rapidly emerging vector-borne Neglected Tropical Disease, with a 30-fold increase in the number of cases reported since 1960. The economic cost of the illness is measured in the billions of dollars annually. Environmental change and unplanned urbanization are conspiring to raise the health and economic cost even further beyond the reach of health systems and households. The health-sector response has depended in large part on control of the Aedes aegypti and Ae...
August 14, 2017: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/28797534/current-status-of-therapeutic-and-vaccine-approaches-against-zika-virus
#7
REVIEW
Braira Wahid, Amjad Ali, Shazia Rafique, Muhammad Idrees
Zika virus (ZIKV) is a global threat because it is spreading at an alarming rate because of its wider range of transmission routes. The neuroteratogenic nature of ZIKV infection is posing serious threats to unborn lives therefore, it is necessary to develop an ideal ZIKV prophylactic or therapeutic agent urgently. Researchers are having tough time finding a treatment for ZIKV in part because of serious consequences of vaccines and drugs to unborn lives and pregnant women. However, in vitro and in vivo evaluation of therapeutic efficacy of DNA vaccine, recombinant subunit vaccine, and ZIKV purified inactivated vaccine offers hope for human protection...
August 7, 2017: European Journal of Internal Medicine
https://www.readbyqxmd.com/read/28794424/virus-like-particles-that-display-zika-virus-envelope-protein-domain-iii-induce-potent-neutralizing-immune-responses-in-mice
#8
Ming Yang, Huafang Lai, Haiyan Sun, Qiang Chen
Several Zika virus (ZIKV) vaccine candidates have recently been described which use inactivated whole virus, DNA or RNA that express the virus' Envelope (E) glycoprotein as the antigen. These were successful in stimulating production of virus-targeted antibodies that protected animals against ZIKV challenges, but their use potentially will predispose vaccinated individuals to infection by the related Dengue virus (DENV). We have devised a virus like particle (VLP) carrier based on the hepatitis B core antigen (HBcAg) that displays the ZIKV E protein domain III (zDIII), and shown that it can be produced quickly and easily purified in large quantities from Nicotiana benthamiana plants...
August 9, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28794181/a-neutralization-assay-for-zika-and-dengue-viruses-using-a-real-time-pcr-based-endpoint-assessment
#9
Heather L Wilson, Thomas Tran, Julian Druce, Myrielle Dupont-Rouzeyrol, Michael Catton
The global spread and infective complications of Zika virus (ZKV) and Dengue virus (DENV) have made them flaviviruses of public health concern. Serological diagnosis can be challenging due to antibody cross-reactivity, particularly in secondary flavivirus infections or when there is a history of flavivirus vaccination. The virus neutralization assay is considered to be the most specific assay for measurement of anti-flavivirus antibodies. This study describes an assay where neutralization endpoint is measured by real-time PCR, providing results within 72 hours...
August 9, 2017: Journal of Clinical Microbiology
https://www.readbyqxmd.com/read/28794019/development-of-virus-like-particle-vaccine-and-reporter-assay-for-zika-virus
#10
Himanshu Garg, Melina Sedano, Gabrielle Plata, Erin B Punke, Anjali Joshi
Recent worldwide outbreaks of Zika virus (ZIKV) infection and the lack of an approved vaccine raises serious concerns regarding preparedness to combat this emerging virus. We used a Virus Like Particle (VLP) based approach to develop a vaccine and a microneutralization assay against ZIKV. Synthetic C-prM-E (Capsid-preMembrane-Envelope) gene construct of ZIKV was used to generate Reporter Virus Particles (RVPs) that package GFP reporter expressing WNV replicon. The assay was adapted to 96 well format, similar to the Plaque Reduction Neutralization Test (PRNT) and showed high reproducibility with specific detection of ZIKV neutralizing antibodies...
August 9, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28789826/zika-virus-protease-an-antiviral-drug-target
#11
REVIEW
CongBao Kang, Thomas H Keller, Dahai Luo
The recent outbreak of Zika virus (ZIKV) infection has caused global concern due to its link to severe damage to the brain development of foetuses and neuronal complications in adult patients. A worldwide research effort has been undertaken to identify effective and safe treatment and vaccination options. Among the proposed viral and host components, the viral NS2B-NS3 protease represents an attractive drug target due to its essential role in the virus life cycle. Here, we outline recent progress in studies on the Zika protease...
August 5, 2017: Trends in Microbiology
https://www.readbyqxmd.com/read/28783378/the-latest-advancements-in-zika-virus-vaccine-development
#12
Lanying Du, Yusen Zhou, Shibo Jiang
No abstract text is available yet for this article.
August 7, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28768876/monoclonal-antibodies-against-zika-virus-therapeutics-and-their-implications-for-vaccine-design
#13
Qihui Wang, Jinghua Yan, George Fu Gao
Zika virus (ZIKV) has caused global concern due to its association with neurological complications in newborns and adults. Although no approved vaccines or antivirals against ZIKV infection to date, hundreds of monoclonal antibodies (MAbs) have been developed in a short period. Here, we first present a complete picture of the ZIKV MAbs and then focus on the neutralizing mechanisms and immune hot spot uncovered through structural studies, which provide insight for therapeutics and vaccine design.
August 2, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28758019/current-trends-in-zika-vaccine-development
#14
EDITORIAL
Francisco A Lagunas-Rangel, Martha E Viveros-Sandoval, Arturo Reyes-Sandoval
The Zika virus (ZIKV) was first isolated in 1947 in Uganda. While it took 60 years for this virus to cause major outbreaks, an important shift in its ability to cause epidemics took place in the first and second decades of the this century: in 2007 in Yap Island, Micronesia, followed by French Polynesia in 2013 and, finally in 2015 and 2016, when ZIKV infections occurred throughout South America, Central America and the Caribbean, spreading rapidly to reach North America in just a single year. No licensed prophylactic vaccine is yet available but recent efforts towards the development of a vaccine have been remarkable from both the private and public sectors and include new candidate vaccines ranging from the classical live-attenuated or inactivated vaccines to more sophisticated approaches such as mRNA or genetically engineered viral platforms...
July 1, 2017: Journal of Virus Eradication
https://www.readbyqxmd.com/read/28754189/progress-and-works-in-progress-update-on-flavivirus-vaccine-development
#15
REVIEW
Matthew H Collins, Stefan W Metz
Most areas of the globe are endemic for at least one flavivirus, putting billions at risk for infection. This diverse group of viral pathogens causes a range of manifestations in humans from asymptomatic infection to hemorrhagic fever to encephalitis to birth defects and even death. Many flaviviruses are transmitted by mosquitos and have expanded in geographic distribution in recent years, with dengue virus being the most prevalent, infecting approximately 400 million people each year. The explosive emergence of Zika virus in Latin America in 2014 refocused international attention on this medically important group of viruses...
July 25, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28747174/knowledge-and-perceptions-about-zika-virus-in-a-middle-east-country
#16
Sohaila Cheema, Patrick Maisonneuve, Ingmar Weber, Luis Fernandez-Luque, Amit Abraham, Hekmat Alrouh, Javaid Sheikh, Albert B Lowenfels, Ravinder Mamtani
BACKGROUND: Zika virus, an emerging serious infectious disease, is a threat to persons living or travelling to regions where it is currently endemic, and also to contacts of infected individuals. The aim of this study was to assess knowledge about this new public health threat to persons residing in a Middle Eastern country. METHODS: We conducted a survey at several international universities in Qatar to assess knowledge and awareness about this disease. An adapted version of the survey was also conducted using online channels from Qatar...
July 26, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28742857/dna-immunisation-with-dengue-virus-e-protein-domains-i-ii-but-not-domain-iii-enhances-zika-west-nile-and-yellow-fever-virus-infection
#17
Jose L Slon Campos, Monica Poggianella, Sara Marchese, Monica Mossenta, Jyoti Rana, Francesca Arnoldi, Marco Bestagno, Oscar R Burrone
Dengue virus (DENV), the causative agent of dengue disease, is among the most important mosquito-borne pathogens worldwide. DENV is composed of four closely related serotypes and belongs to the Flaviviridae family alongside other important arthropod-borne viral pathogens such as Zika virus (ZIKV), West Nile virus (WNV) and Yellow Fever virus (YFV). After infection, the antibody response is mostly directed to the viral E glycoprotein which is composed of three structural domains named DI, DII and DIII that share variable degrees of homology among different viruses...
2017: PloS One
https://www.readbyqxmd.com/read/28742068/a-peptide-based-viral-inactivator-inhibits-zika-virus-infection-in-pregnant-mice-and-fetuses
#18
Yufeng Yu, Yong-Qiang Deng, Peng Zou, Qian Wang, Yanyan Dai, Fei Yu, Lanying Du, Na-Na Zhang, Min Tian, Jia-Nan Hao, Yu Meng, Yuan Li, Xiaohui Zhou, Jasper Fuk-Woo Chan, Kwok-Yung Yuen, Cheng-Feng Qin, Shibo Jiang, Lu Lu
Zika virus (ZIKV), a re-emerging flavivirus associated with neurological disorders, has spread rapidly to more than 70 countries and territories. However, no specific vaccines or antiviral drugs are currently available to prevent or treat ZIKV infection. Here we report that a synthetic peptide derived from the stem region of ZIKV envelope protein, designated Z2, potently inhibits infection of ZIKV and other flaviviruses in vitro. We show that Z2 interacts with ZIKV surface protein and disrupts the integrity of the viral membrane...
July 25, 2017: Nature Communications
https://www.readbyqxmd.com/read/28740159/human-zika-infection-induces-a-reduction-of-ifn-%C3%AE-producing-cd4-t-cells-and-a-parallel-expansion-of-effector-v%C3%AE-2-t-cells
#19
Eleonora Cimini, Concetta Castilletti, Alessandra Sacchi, Rita Casetti, Veronica Bordoni, Antonella Romanelli, Federica Turchi, Federico Martini, Nicola Tumino, Emanuele Nicastri, Angela Corpolongo, Antonino Di Caro, Gary Kobinger, Alimuddin Zumla, Maria Rosaria Capobianchi, Giuseppe Ippolito, Chiara Agrati
The definition of the immunological response to Zika (ZIKV) infection in humans represents a key issue to identify protective profile useful for vaccine development and for pathogenesis studies. No data are available on the cellular immune response in the acute phase of human ZIKV infection, and its role in the protection and/or pathogenesis needs to be clarified. We studied and compared the phenotype and functionality of T-cells in patients with acute ZIKV and Dengue viral (DENV) infections. A significant activation of T-cells was observed during both ZIKV and DENV infections...
July 24, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28740150/identification-of-putative-unique-immunogenic-zikv-and-denv1-4-peptides-for-diagnostic-cellular-based-tests
#20
Aaron L Oom, Davey Smith, Kevan Akrami
Since the re-emergence of Zika virus in 2014 and subsequent association with microcephaly, much work has focused on the development of a vaccine to halt its spread throughout the world. The mosquito vector that transmits this virus is widespread and responsible for the spread of other arboviridae including Dengue. Current diagnostic methods rely on serologic testing that are complicated by cross reactivity and therefore unable to distinguish Zika from Dengue infection in the absence of virus isolation. We performed an in silico analysis to identify potential epitopes that may stimulate a unique T-lymphocyte response to distinguish prior infection with Zika or Dengue...
July 24, 2017: Scientific Reports
keyword
keyword
114751
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"